Since CRC prognosis may be influenced by PCAT-1, the authors suggested that, once elucidated, the molecular mechanisms by which PCAT-1 is involved in CRC progression may be useful as an adjuvant therapy target. Here, PCAT1 is linked to colorectal carcinoma.